Home
Biologics
Antibodies and antibody-based therapeutics, including monoclonal antibodies (mAbs), bispecific antibodies (bsAbs) and antibody-drug conjugations (ADCs), are powerful tools. While the diversity and complexity of tumors makes it difficult to develop effective drugs, the precision and engineering potential of antibodies makes them a powerful tool to direct the immune system to destroy cancer cells or deliver cytotoxic payloads with high specificity.
In cancer research, “biologics” often refers to antibody-based therapies. Antibodies are powerful tools that can guide the immune system to attack cancer cells.
Within our Workstream, we have developed a unique and efficient immunization method that works especially well against challenging targets – such as low immunogenic membrane proteins.
Antibody-based therapies are a powerful tool in the treatment of cancer, but there are still challenges in discovery and development. We aim to help scientists overcome them.
As a crucial type of cancer therapy, the development of antibody-based therapies must be de-risked and accelerated.
Jump straight to available services Resources
The Biologics workstream of the Oncode Accelerator program focuses on developing antibody-based immune therapy to harness the power of the immune system to tackle cancer.
At the basis of antibody discovery, the Biologics Workstream uses a unique method to generate high affinity antibodies against hard-to-target membrane proteins, alongside novel approaches like single B-cell selection in combination with high-throughput sequencing . Leveraging these technologies and approaches will increase the success rate of finding the best antibody for downstream optimization and clinical validation.
Together with the Oncode Accelerator innovation Platforms (Patient Cohorts, Organoids and Artificial Intelligence) and program partners, the Biologics Workstream will increase the chance of clinical success by, for example, directly screening on patient material for efficacy. Resulting leads will be optimized for developability for downstream manufacturing.
By working closely with fellow experts in lead finding, lead optimization, and (pre-)GMP activities, the Biologics Workstream will truly accelerate preclinical antibody development.
Access state-of-the-art infrastructure, backed by scientific know-how and industry leaders.
Key to the success of the Oncode Accelerator program is the selection and execution of high-quality Demonstrator Projects which aim to both validate the Oncode Accelerator infrastructure while simultaneously addressing unmet medical needs. We invite international cancer researchers, from across academia and industry to apply for a Demonstrator Project and partner with us for preclinical development of promising assets.
By combining the key capabilities of our Workstreams with the innovations from our Platforms we create a synergistic effect resulting in better therapies, tailored to individual patients or patient subgroups.
Click on the arrows below to understand how Oncode Accelerator supports cancer researchers and drug developers in turning antibody assets into de-risked clinical candidates through Demonstrator Projects.
-
Are you looking to...
- Advance a novel antibody format from concept to clinic
- Develop antibodies to target novel antigens
- Develop novel antibodies including difficult to target transmembrane proteins
- Find or optimize your lead antibody candidate
- Perform in vitro characterization & lead optimization through a combination of in silico AI-driven methodology and in vitro selection on patient material and/or organoids?
- Assess the pharmacokinetics of your antibody in humans
- Perform cell line generation, process development and manufacturing of antibodies through a unique (pre-)GMP-infrastructure specialized in early production of biologics, to prepare for Phase I studies
- Access expertise on requirements for later-stage development to de-risk earlier-stage R&D
-
Would you like to utilize...
- A proprietary cell-based method for antibody generation
- Novel antibody discovery techniques, from hybridoma to single plasma cell characterization
- State-of-the-art single cell characterization devices for antibody discovery
- High-throughput screening technologies
- Organoids and other human-derived tumor tissues for lead finding
- A state-of-the-art (pre-)GMP facility to efficiently develop and produce your antibody for clinical studies
-
Why should this be of interest?
The Biologics Workstream offers broad coverage of antibody modalities in-house and through collaboration with world-class partners. Demonstrator Projects can enter the program at various stages of the drug development pipeline, from antibody generation to late-stage efficacy and GMP production. Our three innovation platforms (Patient Cohorts, Organoids and Artificial Intelligence) are integrated at several stages in order to de-risk and accelerate the development process.
By increasing the initial number of antibodies to be screened, screening on clinically relevant material, and manufacturing more complex antibody constructs for clinical validation, the success rate of finding the best antibody for downstream optimization and clinical validation should be increased. In addition, this should reduce the time and cost for therapy development, through early de-selection due to detection/predicting of liabilities, early process guidance for clinical manufacturing, direct toxicity analysis in phase 0 studies, and an optimized workflow design.
Patient Cohorts Organoids Artificial Intelligence
A Demonstrator Project can be executed at any stage of the Workstream pipeline and incorporates at least one of the innovative Platforms (Patient Cohorts, Organoids and/or Artificial Intelligence). The stages are designed to ensure that potential oncology therapies are thoroughly evaluated and de-risked before moving on to clinical trials. One stage of a pipeline will be one Demonstrator Project, eligible for up to 50% co-funding.
Contact us and learn more about how to join our program.
Oncode Accelerator is a dynamic collaboration of more than 35 public and private partners. The following consortium partners are part of the Biologics Workstream.
Below is a curated selection of scientific publications by the Workstream Biologics. Click on each publication to access the full text online.